Research
Overcoming therapeutic resistance in cancer
… points out, “Patients whose average survival was six months for advanced cancers have had their survival extended … of an inhibitory drug blocks its activity by binding to its active site, but if a secondary mutation occurs which alters … This ERC Starting Grant is coming to an end in a few months' time. An application has been made for the next …Published on: